New drug bimekizumab shows promise for psoriasis in early trial

NCT ID NCT03025542

Completed Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tested the drug bimekizumab in 49 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab or a placebo, and researchers measured how well the drug cleared skin and how long it stayed in the body. The goal was to see if bimekizumab could be a safe and effective treatment for this chronic skin condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bimekizumab
What this could lead to: If successful, this could lead to a new treatment option for people with moderate to severe plaque psoriasis, helping to clear skin and reduce symptoms.
What could go wrong: This was a small, early-phase study (Phase 2) with only 49 participants. Larger trials are needed to confirm safety and effectiveness. Some participants may still experience side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC PLAQUE PSORIASIS

Contacts and locations

Locations

Ps0016 101

Melbourne, Australia
Ps0016 102

Kogarah, Australia
Ps0016 104

Woolloongabba, Australia
Ps0016 201

Ajax, Canada
Ps0016 202

Windsor, Canada
Ps0016 203

London, Canada
Ps0016 501

Chisinau, Moldova
Ps0016 704

Bexley, Ohio, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.